pharmaphorum14d
Catalyst throws lifeline to Santhera with $90m Duchenne deal
Swiss biotech Santhera has found a North American partner for its Duchenne muscular dystrophy (DMD) therapy vamorolone, ahead of an FDA decision on the drug due by 26th October. Florida-based rare ...
ENDPOINTS NEWS16d
No­var­tis en­ters fight against HHS for deny­ing its 340B re­bate mod­el
No­var­tis is the lat­est drug­mak­er to sue the gov­ern­ment for al­leged­ly re­ject­ing its pro­posed mod­el to dis­trib­ute fed­er­al drug dis­counts.
Outsourcing-pharma16d
Transforming research through patient-centric design and innovation
The evolution of clinical trials is being driven by an increased focus on patient perspectives and innovative statistical methodologies. Regulatory agencies are pushing for trials that better ...
Yahoo Finance16d
Santhera Pharmaceuticals Provides Update on Royalty Agreement for AGAMREE® (Vamorolone) and Warrants held by Idorsia
Pratteln, Switzerland, January 16, 2025 – Santhera Pharmaceuticals (SIX: SANN) announces that Idorsia Pharmaceuticals has entered into a royalty monetization agreement with the R-Bridge ...
Morningstar17d
Santhera Receives Positive NICE Final Guidance for AGAMREE® (Vamorolone) as a Treatment for Duchenne Muscular Dystrophy
Pratteln, Switzerland, January 16, 2025 – Santhera Pharmaceuticals (SIX: SANN) announces that the National Institute for Health and Care Excellence (NICE) has issued positive Final Guidance ...